Venn Life Sciences Holdings Stock London S.E.
Equities
GB00B9275X97
Biotechnology & Medical Research
Sales 2023 | 56.04M 69.32M | Sales 2024 * | 62.07M 76.77M | Capitalization | 182M 225M |
---|---|---|---|---|---|
Net income 2023 | 16M 19.79M | Net income 2024 * | 9M 11.13M | EV / Sales 2023 | 2.88 x |
Net cash position 2023 * | 34.79M 43.04M | Net cash position 2024 * | 41.48M 51.31M | EV / Sales 2024 * | 2.26 x |
P/E ratio 2023 |
10.1
x | P/E ratio 2024 * |
21.1
x | Employees | - |
Yield 2023 * |
1.52% | Yield 2024 * |
0.87% | Free-Float | 60.77% |
Latest transcript on Venn Life Sciences Holdings
Managers | Title | Age | Since |
---|---|---|---|
Yamin Khan
CEO | Chief Executive Officer | 55 | 21-10-12 |
Ian O'Connell
FOU | Founder | 37 | 11-01-31 |
Cathal Friel
FOU | Founder | 59 | 11-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 57 | 22-06-07 | |
Cathal Friel
FOU | Founder | 59 | 11-01-31 |
Brendan Buckley
FOU | Founder | 73 | 18-11-30 |
1st Jan change | Capi. | |
---|---|---|
-1.42% | 41.52B | |
+42.15% | 39.9B | |
+1.97% | 38.83B | |
-14.19% | 26.05B | |
+1.82% | 23.78B | |
-24.55% | 18.26B | |
-4.07% | 11.65B | |
+21.36% | 11.53B | |
+8.20% | 11.2B |